A tailored web program to boost exercise and healthy eating for pancreatic cancer patients before surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial examines a tailored, web-based portal (COMPASS) designed for patients with stage I–III pancreatic cancer undergoing neoadjuvant chemotherapy. Participants are assigned to either access to the COMPASS portal with tailored exercise and diet guidance plus optional support sessions, or the portal with the same guidance minus the optional coaching cadence. The study will measure acceptability, feasibility, and preliminary effectiveness on exercise and diet behaviors, self-efficacy, well-being, and treatment tolerance at baseline, 3 months, and end of chemotherapy. Primary objectives include accrual, retention, and portal usage; secondary objectives assess behavior change and well-being; tertiary objectives compare single versus monthly health coaching. The trial is conducted at OHSU Knight Cancer Institute with collaboration from Oregon Health & Science University.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older on date of enrollment

  * Confirmed by review of the date of birth as documented in the electronic medical record (EMR) and subsequently recorded in a case report form (CRF)
* Diagnosed with stage I-III pancreatic cancer

  * Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm
* Scheduled to receive neoadjuvant chemotherapy at Oregon Health \& Science University (OHSU)

  * Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm
* Willing to adhere to the study protocol

  * Confirmed verbally with the participant and response documented in the Participant Tracking database

Exclusion Criteria:

* Cognitive difficulties that preclude answering the survey questions, participating in the intervention, or giving informed consent

  * In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the Principal Investigators, Dr. Kerri Winters-Stone and/or Dr. Jackilen Shannon
* A medical condition, movement or neurological disorder, or medication use that contraindicates participation in light intensity exercise

  * Confirmed by a combination of reviewing the EMR, and self-report during the initial screening call. If in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone or Dr. Jackilen Shannon, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible
* Not fluent in English and therefore incapable of answer survey questions, reading the intervention web portal, and providing informed consent in English

  * Confirmed verbally with the participant and response documented in the Participant Tracking database

Where it's running

• OHSU Knight Cancer Institute
  Portland, Oregon, United States Recruiting

Study contacts

• Principal investigator: Kerri Winters-Stone — OHSU Knight Cancer Institute

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant chemotherapy for resectable pancreatic cancer

  This study is testing a combination of three chemotherapy drugs to see if it helps people with resectable pancreatic cancer get better before surgery.

  Recruiting Phase 2 Georgetown University · Washington D.C., District of Columbia and 1 other locations · NCT06423326

• AB801 with chemotherapy and immunotherapy for cholangiocarcinoma and pancreatic cancer

  This phase 1 study tests whether AB801 can be given safely with chemotherapy and immunotherapy in adults with border-line resectable, locally advanced, or metastatic cholangiocarcinoma or pancreatic cancer.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07619313

• OMO-103 for advanced or metastatic pancreatic ductal adenocarcinoma

  This trial tests an experimental IV drug called OMO-103 to see if it changes tumor cells in adults with locally advanced or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Early Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT07089940

• Higher-dose targeted radiation for locally advanced pancreatic cancer

  This tests whether giving a higher, precisely targeted dose of radiation after initial chemotherapy helps people with locally advanced unresectable pancreatic cancer live longer.

  Recruiting at 327 sites Phase 3 NRG Oncology · Gilbert, Arizona and 332 other locations · NCT06958328

• Using pemigatinib to treat advanced pancreatic cancer with FGFR genetic changes

  This study is testing if a new drug called pemigatinib can help adults with advanced pancreatic cancer that has specific genetic changes feel better and possibly live longer.

  Recruiting at 109 sites Phase 2 Ohio State University Comprehensive Cancer Center · Birmingham, Alabama and 108 other locations · NCT06906562

• CPI-613 combined with hydroxychloroquine and chemotherapy for advanced solid tumors

  This study is testing a new combination of treatments, including CPI-613 and hydroxychloroquine, to see if it can help people with advanced solid tumors that haven't improved with other chemotherapy.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT05733000

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.